相似文献
1
Antipneumococcal activities of a ketolide (HMR 3647), a streptogramin (quinupristin-dalfopristin), a macrolide (erythromycin), and a lincosamide (clindamycin).
Antimicrob Agents Chemother. 1998 Apr;42(4):945-6. doi: 10.1128/AAC.42.4.945.
2
[Streptococcus pneumoniae strains resistance to macrolide, lincosamide, streptogramin, oxazolidinone and ketolide].
Mikrobiyol Bul. 2002 Apr;36(2):125-31.
3
In vitro activity of telithromycin against Spanish Streptococcus pneumoniae isolates with characterized macrolide resistance mechanisms.
Antimicrob Agents Chemother. 2001 Sep;45(9):2427-31. doi: 10.1128/AAC.45.9.2427-2431.2001.
4
Activity of the ketolide telithromycin (HMR-3647) against erythromycin-susceptible and -resistant pneumococci isolated in the UK.
Int J Antimicrob Agents. 2001 Jul;18(1):73-6. doi: 10.1016/s0924-8579(01)00346-6.
5
In vitro activity of telithromycin and quinupristin/dalfopristin against methicillin-resistant coagulase-negative staphylococci with defined resistance genotypes.
Folia Microbiol (Praha). 2007;52(6):593-9. doi: 10.1007/BF02932188.
6
Activity of quinupristin-dalfopristin in invasive isolates of Streptococcus pneumoniae from Italy.
Clin Microbiol Infect. 2001 Sep;7(9):503-6. doi: 10.1046/j.1198-743x.2001.00298.x.
7
Patterns of phenotypic resistance to the macrolide-lincosamide-ketolide-streptogramin group of antibiotics in staphylococci.
J Antimicrob Chemother. 2000 Dec;46(6):941-9. doi: 10.1093/jac/46.6.941.
8
Prevalence and characterization of the mechanisms of macrolide, lincosamide, and streptogramin resistance in isolates of Streptococcus pneumoniae.
Antimicrob Agents Chemother. 1998 Sep;42(9):2425-6. doi: 10.1128/AAC.42.9.2425.
9
In vitro activity of ketolides telithromycin and HMR 3004 against italian isolates of Streptococcus pyogenes and Streptococcus pneumoniae with different erythromycin susceptibility.
J Antimicrob Chemother. 2000 Dec;46(6):905-8. doi: 10.1093/jac/46.6.905.
10
In vitro activity of the new ketolide HMR 3004 compared to an azalide and macrolides against Streptococcus pneumoniae and Haemophilus influenzae.
Eur J Clin Microbiol Infect Dis. 1997 Oct;16(10):767-9. doi: 10.1007/BF01709263.
引用本文的文献
1
Ketolides in the treatment of community-acquired respiratory tract infections: A review.
Curr Ther Res Clin Exp. 2005 May;66(3):139-53. doi: 10.1016/j.curtheres.2005.06.008.
2
Pharmacodynamic profile of telithromycin against macrolide- and fluoroquinolone-resistant Streptococcus pneumoniae in a neutropenic mouse thigh model.
Antimicrob Agents Chemother. 2005 Jan;49(1):188-94. doi: 10.1128/AAC.49.1.188-194.2005.
3
Activities of cethromycin and telithromycin against recent North American isolates of Streptococcus pneumoniae.
Antimicrob Agents Chemother. 2004 Feb;48(2):605-7. doi: 10.1128/AAC.48.2.605-607.2004.
4
Fluoroquinolone and macrolide treatment failure in pneumococcal pneumonia and selection of multidrug-resistant isolates.
Emerg Infect Dis. 2003 Sep;9(9):1159-62. doi: 10.3201/eid0909.020810.
5
In vitro activities of telithromycin and 10 oral agents against aerobic and anaerobic pathogens isolated from antral puncture specimens from patients with sinusitis.
Antimicrob Agents Chemother. 2003 Jun;47(6):1963-7. doi: 10.1128/AAC.47.6.1963-1967.2003.
6
Dead bugs don't mutate: susceptibility issues in the emergence of bacterial resistance.
Emerg Infect Dis. 2003 Jan;9(1):10-6. doi: 10.3201/eid0901.020172.
7
Antibiotic susceptibilities of Parachlamydia acanthamoeba in amoebae.
Antimicrob Agents Chemother. 2002 Sep;46(9):3065-7. doi: 10.1128/AAC.46.9.3065-3067.2002.
8
The ketolides: a critical review.
Drugs. 2002;62(12):1771-804. doi: 10.2165/00003495-200262120-00006.
9
Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in Canada during 2000.
Antimicrob Agents Chemother. 2002 May;46(5):1295-301. doi: 10.1128/AAC.46.5.1295-1301.2002.
10
Bronchopulmonary disposition of the ketolide telithromycin (HMR 3647).
Antimicrob Agents Chemother. 2001 Nov;45(11):3104-8. doi: 10.1128/AAC.45.11.3104-3108.2001.
本文引用的文献
1
Macrolide resistance among Streptococcus pneumoniae and Streptococcus pyogenes isolates from out-patients in the USA.
J Antimicrob Chemother. 1997 Jul;40(1):139-40. doi: 10.1093/jac/40.1.139.
2
Antimicrobial activity of RU-66647, a new ketolide.
Diagn Microbiol Infect Dis. 1997 Jan-Feb;27(1-2):7-12. doi: 10.1016/s0732-8893(96)00181-2.
3
Novel mechanism of macrolide resistance in Streptococcus pneumoniae.
Diagn Microbiol Infect Dis. 1996 Oct;26(2):73-8. doi: 10.1016/s0732-8893(96)00183-6.
4
Variation in erythromycin and clindamycin susceptibilities of Streptococcus pneumoniae by four test methods.
Antimicrob Agents Chemother. 1997 Jan;41(1):129-34. doi: 10.1128/AAC.41.1.129.
5
Clindamycin resistance among erythromycin-resistant Streptococcus pneumoniae.
Diagn Microbiol Infect Dis. 1996 Aug;25(4):201-4. doi: 10.1016/s0732-8893(96)00100-9.
6
Comparative in-vitro activity of quinupristin/dalfopristin (RP 59500) tested against penicillin-and macrolide-resistant pneumococci by the Etest.
J Antimicrob Chemother. 1996 Sep;38(3):553-5. doi: 10.1093/jac/38.3.553.
7
Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system.
Antimicrob Agents Chemother. 1996 Aug;40(8):1817-24. doi: 10.1128/AAC.40.8.1817.
8
Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study.
Antimicrob Agents Chemother. 1996 May;40(5):1208-13. doi: 10.1128/AAC.40.5.1208.
9
In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from U.S. Medical Centers in 1992 and 1993.
Antimicrob Agents Chemother. 1994 Oct;38(10):2419-25. doi: 10.1128/AAC.38.10.2419.
Zotero 插件